M.C. Isernia

103P Time-dependent censoring imbalance and robustness of PFS and OS estimates in trials supporting EMA approval of first-line anti–PD-1/PD-L1 therapy for PD-L1–high advanced NSCLC

F. Vitale, S. D'Ambrosio, Annarita Avanzo, M.C. Isernia et autres

In first-line advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%, immune checkpoint inhibitors (ICIs) improve progression-free survival (PFS) and overall survival (OS). Standard survival analyses assume non-informative censoring, an assumption that may be violated in open-label immunotherapy trials. We assessed the …

it (code pays fourni par la source)

170P AI-assisted systematic review and pooled analysis of anthracycline- versus taxane-based chemotherapy in advanced or metastatic angiosarcoma

Annarita Peddio, S. D'Ambrosio, F. Vitale, Annarita Avanzo et autres

Comparative evidence for first-line anthracycline- (Ant) vs taxane-based (Tax) chemotherapy in advanced angiosarcoma (AS) is limited by small, heterogeneous retrospective studies. We performed an AI-assisted systematic review and pooled analysis to overcome fragmented reporting and evaluate efficacy and safety across clinically relevant …

it (code pays fourni par la source)

118P: Assessing informative censoring in trials testing immunecheckpoint inhibitors in NSCLC: A systematic review and a meta-research study

Francesca Vitale, Sasha D’Ambrosio, Annarita Avanzo, F. Salomone et autres

it (code pays fourni par la source)

65P Correlation of overall survival and surrogate endpoints in advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A trial-level analysis

F. Salomone, F. Napolitano, A. Caltavituro, R. Buonaiuto et autres

it (code pays fourni par la source)